Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 320

1.

Adjuvants for human vaccines--current status, problems and future prospects.

Gupta RK, Siber GR.

Vaccine. 1995 Oct;13(14):1263-76. Review.

PMID:
8585280
2.

Adjuvants--a balance between toxicity and adjuvanticity.

Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben-Efraim S, Gupta CK.

Vaccine. 1993;11(3):293-306. Review.

PMID:
8447157
3.

Biodegradable polymer microspheres as vaccine adjuvants and delivery systems.

Gupta RK, Chang AC, Siber GR.

Dev Biol Stand. 1998;92:63-78. Review.

PMID:
9554260
4.

The role of adjuvants in retroviral vaccines.

Vogel FR.

Int J Immunopharmacol. 1995 Feb;17(2):85-90. Review.

PMID:
7657411
5.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
6.

Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.

Vandepapelière P, Horsmans Y, Moris P, Van Mechelen M, Janssens M, Koutsoukos M, Van Belle P, Clement F, Hanon E, Wettendorff M, Garçon N, Leroux-Roels G.

Vaccine. 2008 Mar 4;26(10):1375-86. doi: 10.1016/j.vaccine.2007.12.038. Epub 2008 Jan 14.

PMID:
18272264
7.

Recent advances in vaccine adjuvants for systemic and mucosal administration.

O'Hagan DT.

J Pharm Pharmacol. 1998 Jan;50(1):1-10. Review.

PMID:
9504429
8.

Novel adjuvants and vaccine delivery systems.

Morein B, Villacrés-Eriksson M, Sjölander A, Bengtsson KL.

Vet Immunol Immunopathol. 1996 Nov;54(1-4):373-84.

PMID:
8988882
9.

What are the limits of adjuvanticity?

Del Giudice G, Podda A, Rappuoli R.

Vaccine. 2001 Oct 15;20 Suppl 1:S38-41.

PMID:
11587808
10.

Adjuvants in perspective.

Vogel FR.

Dev Biol Stand. 1998;92:241-8. Review.

PMID:
9554280
11.

Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators.

Nordly P, Madsen HB, Nielsen HM, Foged C.

Expert Opin Drug Deliv. 2009 Jul;6(7):657-72. doi: 10.1517/17425240903018863. Review.

PMID:
19538037
12.

Unmet needs in modern vaccinology: adjuvants to improve the immune response.

Leroux-Roels G.

Vaccine. 2010 Aug 31;28 Suppl 3:C25-36. doi: 10.1016/j.vaccine.2010.07.021. Review.

PMID:
20713254
13.

ISCOMs (immunostimulating complexes): the first decade.

Barr IG, Mitchell GF.

Immunol Cell Biol. 1996 Feb;74(1):8-25. Review.

14.

Starch microparticles as vaccine adjuvant.

Rydell N, Stertman L, Sjöholm I.

Expert Opin Drug Deliv. 2005 Sep;2(5):807-28. Review.

PMID:
16296780
15.

Inulin-derived adjuvants efficiently promote both Th1 and Th2 immune responses.

Silva DG, Cooper PD, Petrovsky N.

Immunol Cell Biol. 2004 Dec;82(6):611-6. Review.

16.

Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.

Perrie Y, Mohammed AR, Kirby DJ, McNeil SE, Bramwell VW.

Int J Pharm. 2008 Dec 8;364(2):272-80. doi: 10.1016/j.ijpharm.2008.04.036. Epub 2008 Apr 30. Review.

PMID:
18555624
17.

Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants.

Berthold I, Pombo ML, Wagner L, Arciniega JL.

Vaccine. 2005 Mar 14;23(16):1993-9.

PMID:
15734073
18.

Design and selection of vaccine adjuvants: animal models and human trials.

Alving CR.

Vaccine. 2002 May 31;20 Suppl 3:S56-64. Review.

PMID:
12184368
19.

Antitumor vaccination: where we stand.

Bocchia M, Bronte V, Colombo MP, De Vincentiis A, Di Nicola M, Forni G, Lanata L, Lemoli RM, Massaia M, Rondelli D, Zanon P, Tura S.

Haematologica. 2000 Nov;85(11):1172-206. Review.

20.

Adjuvant properties of aluminum and calcium compounds.

Gupta RK, Rost BE, Relyveld E, Siber GR.

Pharm Biotechnol. 1995;6:229-48. Review.

PMID:
7551219

Supplemental Content

Support Center